Novomix Flexpen
Novomix 30 Flexpen Insulin 100 IU/ml pen 3 ml 5 pens

Novomix 30 Flexpen Insulin 100 IU/ml pen 3 ml 5 pens

$120.00

Novomix 30 Flexpen Insulin 100 IU/ml pen 3 ml 5 pens

 

Manufactured By NOVO NORDISK
Clear
  • US domestic free shipping 3-5 days
  • Worldwide free shipping 10-20 days
  • WhatsApp/Viber: +1-484-263-47-88
Guaranteed Safe Checkout

Description

Novomix 30 Flexpen Injection is a combination of a fast-acting and intermediate-acting analogs of insulin used for the treatment of diabetes mellitus.

Insulin is a natural substance produced by the pancreas which helps in utilizing glucose for energy production.

Patients with diabetes mellitus may not be able to utilize glucose due to the insufficient production of insulin or due to the body’s inability to use insulin or both.

This medicine helps in the utilization of glucose and controlling blood glucose levels in such patients. Patients are advised to follow a strict exercise and diet regimen along with this medicine to get the best possible effect.

Side effects

Major & minor side effects for Novomix 30 Flexpen Injection

  • Decreased blood glucose levels
  • Headache
  • Pain at injection site
  • Dizziness
  • Drowsiness
  • Tingling of hands, feet, lips or tongue
  • Confusion
  • Unusual weight gain or loss

Uses of Novomix 30 Flexpen Injection

What is it prescribed for?

  • Type I Diabetes mellitus
    This medicine is used in the treatment of Type 1 Diabetes mellitus, a lifelong condition in which the pancreas does not produce sufficient insulin to control the blood sugar levels.
  • Type II Diabetes Mellitus
    This medicine is used in the treatment of Type II Diabetes Mellitus, a lifelong condition in which the insulin produced by the body cannot be used properly by the cells to convert glucose into energy.

Additional information

Warehouse

International warehouse, US warehouse

Reviews

There are no reviews yet.

Be the first to review “Novomix 30 Flexpen Insulin 100 IU/ml pen 3 ml 5 pens”

Your email address will not be published.